Merck shares dive after multiple firms downgrade on cancer drug withdrawal – CNBC

Merck shares dive after multiple firms downgrade on cancer drug withdrawal
CNBC
Merck announced lung cancer trial result delays and that it was pulling its application to market key oncology drug Keytruda for lung cancer in the EU on Friday. Analysts at Morgan Stanley, Barclays and SunTrust Robinson Humphrey all downgraded the …
Merck's Price Strength Is AilingTheStreet.com
Merck (MRK) Defended at BMO CapitalStreetInsider.com
Merck: Appeal Lures Driven By Keytruda As The 'Core' StrugglesSeeking Alpha
BioPharma Dive –Motley Fool –Financialbuzz.com –StockNewsTimes
all 179 news articles »